
Opinion|Videos|January 22, 2025
Long-Term Safety of Second-Line Therapies for PBC
Panelists discuss how long-term safety monitoring for second-line primary biliary cholangitis (PBC) therapies requires systematic assessment of liver function, lipid profiles, and potential drug-specific adverse effects while emerging 5-year safety data for seladelpar continues to demonstrate a favorable risk profile compared with other treatment options.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the potential risks of long-term therapy with seladelpar, elafibranor, and obeticholic acid, and how can clinicians monitor for and mitigate these risks?
- Discuss the 5-year safety data for seladelpar presented at AASLD 2024.
- Discuss the 5-year safety data for seladelpar presented at AASLD 2024.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
2
Investigational mRNA Flu Vaccine Broadens Antibody Defenses, Sustains Immune "Training Hub" Longer Than Standard Shot
3
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
4
Bringing Bispecific Therapy Into the Outpatient Community Oncology Setting
5





































































































